RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025

Jun 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-06-03

Reporting Person: MCGIRR DAVID W J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-03	Common Stock	M	65431	$4.59	Acquired	68431	Direct
2025-06-03	Common Stock	S	55558	$65.1464	Disposed	12873	Direct
2025-06-03	Common Stock	S	9873	$65.6427	Disposed	3000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-03	Stock Option (Right to Buy)	$4.59	M	65431	Disposed	2025-11-16	Common Stock (65431)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.

F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.59 to $65.81 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The stock option is fully vested.